Loading...
XWAR
MAB
Market cap41mUSD
Jul 31, Last price  
9.69PLN
1D
0.41%
1Q
-11.36%
Jan 2017
-86.96%
IPO
-28.03%
Name

Mabion SA

Chart & Performance

D1W1MN
P/E
3.79
P/S
1.03
EPS
2.55
Div Yield, %
Shrs. gr., 5y
4.31%
Rev. gr., 5y
%
Revenues
152m
-7.50%
01,527,582985,375884,7845,800829,7002,733,0000000056,873,000163,982,000151,678,000
Net income
41m
+77.94%
0471,44900-3,891,200-4,461,200-4,597,000-55,826,000-57,887,000-68,870,000-64,708,000-57,188,0001,903,00023,192,00041,269,000
CFO
-2m
L
0000-27,589,100-24,386,500-33,969,000-15,221,000-54,127,000-38,938,000-33,755,000-35,239,000-32,910,00038,839,000-2,333,000
Earnings
Sep 08, 2025

Profile

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.
IPO date
Aug 10, 2010
Employees
248
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
151,678
-7.50%
163,982
188.33%
Cost of revenue
83,516
141,773
Unusual Expense (Income)
NOPBT
68,162
22,209
NOPBT Margin
44.94%
13.54%
Operating Taxes
8,625
(1,152)
Tax Rate
12.65%
NOPAT
59,537
23,361
Net income
41,269
77.94%
23,192
1,118.71%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
32,880
3,087
Long-term debt
7,248
10,960
Deferred revenue
31,802
31,172
Other long-term liabilities
405
(377)
Net debt
(7,689)
(39,811)
Cash flow
Cash from operating activities
(2,333)
38,839
CAPEX
(37,997)
(16,731)
Cash from investing activities
(37,982)
(16,064)
Cash from financing activities
34,494
(17,844)
FCF
16,709
22,313
Balance
Cash
47,817
53,638
Long term investments
220
Excess cash
40,233
45,659
Stockholders' equity
(119,667)
(160,936)
Invested Capital
305,478
275,518
ROIC
20.49%
8.26%
ROCE
36.68%
19.32%
EV
Common stock shares outstanding
16,162
16,162
Price
18.15
-13.57%
21.00
-65.63%
Market cap
293,346
-13.57%
339,401
-64.29%
EV
285,657
299,590
EBITDA
75,361
31,186
EV/EBITDA
3.79
9.61
Interest
1,038
1,698
Interest/NOPBT
1.52%
7.65%